BioSpace News Archive

Small molecule drug discovery acceleration experts and DNA-encoded library technology pioneers X-Chem, Inc. welcomes Paul Davie as Chief Business Officer.

Escend Pharmaceuticals, Inc. announced today a poster presentation with initial data from the Australasian Leukaemia and Lymphoma Group’s (ALLG) investigator-initiated Phase I/II platform study.

Ferring Pharmaceuticals today launched a new Male Fertility program on Ferring’s Fertility Out Loud platform that empowers men to take the initiative to understand their fertility status.

Arcturus Therapeutics Holdings Inc. today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company’s Board of Directors.

Allurion Technologies, Inc., a company dedicated to ending obesity, announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program.

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports follow-up results from the second, third and fourth patients enrolled in its Deltacel-01 Phase 1 clinical trial.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced preclinical data from two separate research collaborations.

NewGenIvf Group, a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, announced that the Company is continuing to actively evaluate the terms of the proposed reverse merger with COVIRIX Medical Pty Ltd.

HotSpot Therapeutics, Inc. today announced the presentation of preclinical data from the Company’s highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program at the 4th American Association for Cancer Research (AACR) International Meeting: Advances in Malignant Lymphoma.

Silence Therapeutics plc today announced positive topline 48-week data from the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events.